NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences shows new long‑term data for VYKAT XR and CR NESSITY, boosting market access, pricing strategy, and M&A prospects in rare endocrine diseases.

Neurocrine’s latest INGREZZA data shows high remission rates and safety in hepatic‑impaired and IDD patients, boosting payer value, market share, and growth prospects before the 2030s patent cliff.

Neurocrine Biosciences’ May 29, 2026 insider trades show senior staff buying shares, exercising NQSOs and RSUs, and filing a Rule 144 to boost liquidity—transparent moves that underscore strong governance and regulatory compliance in the biotech sec…

Neurocrine Biosciences completes $2.9 B Soleno Therapeutics acquisition and secures a $1 B credit line, boosting its neuro‑psychiatric pipeline and market positioning.

Neurocrine Biosciences insider sale reveals governance, equity‑compensation strategy and market positioning for investors, highlighting confidence in its neuro‑therapeutic pipeline.

Neurocrine Biosciences (NBIX) sees a 40% upside from earnings revisions and a strong neuro‑oncology pipeline, but faces regulatory and reimbursement risks that investors must monitor.

Neurocrine Biosciences’ $2.9 billion acquisition of Soleno Therapeutics expands its neuro‑oncology pipeline, adding precision ADCs like SLO‑101 and SLO‑204 with promising early efficacy and a strong regulatory roadmap.

Neurocrine’s $2.9 B acquisition of Soleno adds FDA‑approved VYKAT XR for Prader‑Willi, expanding its rare‑disease portfolio with proven efficacy and a strong safety profile.

Neurocrine’s $2.9 B acquisition of Soleno Therapeutics unlocks Vykat XR’s rare‑disorder revenue, boosting margins and diversifying into a high‑growth, low‑competition market.

Neurocrine Biosciences will host a live investor webinar on March 17, revealing CNS‑forum insights, pipeline progress, and strategic partnerships for neurological & endocrine therapies.